{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:51:46Z","timestamp":1774569106785,"version":"3.50.1"},"reference-count":35,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d: low dose dexamthasone) regimen is widely used due to its high effectiveness, low toxicity and good tolerability, particularly with renal impairment. Real-world data on the use of VCD in clinical practice is lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Evaluate the real-world experience of the VCD regimen<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Tumor registry database of tertiary cancer care center<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Newly diagnosed MM patients who received VCD induction and underwent autologous stem cell transplant (ASCT) from July 2007 to July 2020<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>Response evaluation, progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>87 patients<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              Of 102 patients who started induction with VCd, 87 patients experienced a partial response or more overall response rate of 85%). The median age of these 87 patients at diagnosis was 52 years, of which 29.9% presented with renal impairment and 60.3% of patients had stage 2 by the Revised International Staging System (R-ISS). Patients with a standard cytogenetic risk achieved a better response compared to those with a poor cytogenetic risk (\n              <jats:italic>P<\/jats:italic>\n              =.044). The post-induction response rates were 6.9% stringent complete remission (sCR), 35% complete remission (CR); 41.4% very good partial response (VGPR), and 16.1% partial response (PR), respectively; the response rates became greater for sCR and CR post-transplantation at day 100 with 16.1% sCR, 35.6% CR, 32.2% VGPR and 16.1% PR, respectively. The median PFS was 49 months and 5 years OS was 84%. PFS was better in patients who achieved sCR vs PR (83 vs 35 months,\n              <jats:italic>P<\/jats:italic>\n              =.037). High LDH, high-risk cytogenetic and stage 3 R-ISS showed a worse median PFS and OS.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>VCD induction in newly diagnosed MM is highly effective, convenient, tolerable and affordable regimen, especially in low and middle-income countries with limited resources, also with favorable outcomes and survival. while those who did not respond successfully shifted to VRD or VTD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>The usual limitations of a retrospective analysis using registry-level data, no data on quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2024.93","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T05:01:38Z","timestamp":1713070898000},"page":"93-103","source":"Crossref","is-referenced-by-count":1,"title":["Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients"],"prefix":"10.5144","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-990X","authenticated-orcid":true,"given":"Ahmed Kotb","family":"Abdrabou","sequence":"first","affiliation":[{"name":"From the Department of Hematology and Bone Marrow Transplant, Zagazig University, Zagazig, Egypt"},{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Al Sharif","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazaa Al","family":"Zahrani","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruah","family":"Al Yamany","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Saleh","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Alhayli","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakia","family":"Al Somali","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AlFadel","family":"AlShaibani","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Deeba","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Asif","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ahmed Osman Ali","family":"Ahmed","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Al Fraih","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Shaheen","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Rasheed","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeem Arshad","family":"Chaudhri","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Al Mohareb","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Hanbali","sequence":"additional","affiliation":[{"name":"From the Adult Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"issue":"3","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima T","year":"2004","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104(3):607\u201318.","journal-title":"Blood."},{"issue":"1","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig H","year":"2010","unstructured":"Ludwig H, Beksac M, Blad\u00e9 J, Boccadoro M, Cavenagh J, Cavo M, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. The oncologist. 2010;15(1):6.","journal-title":"The oncologist."},{"issue":"5","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Leiba M","year":"2014","unstructured":"Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. British journal of haematology. 2014;166(5):702\u201310.","journal-title":"British journal of haematology."},{"issue":"10","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ajh.23810","article-title":"Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management","volume":"89","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. American journal of hematology. 2014;89(10):998\u20131009.","journal-title":"American journal of hematology."},{"issue":"3","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.hemonc.2017.05.027","article-title":"Comparison of cyclophosphamide\u2013thalidomide\u2013dexamethasone to bortezomib\u2013cyclophosphamide\u2013dexamethasone as induction therapy for multiple myeloma patients in Brazil","volume":"10","author":"Vigolo S","year":"2017","unstructured":"Vigolo S, Zuckermann J, Bittencourt RI, Silla L, Pilger DA. Comparison of cyclophosphamide\u2013thalidomide\u2013dexamethasone to bortezomib\u2013cyclophosphamide\u2013dexamethasone as induction therapy for multiple myeloma patients in Brazil. Hematology\/oncology and stem cell therapy. 2017;10(3):135\u201342.","journal-title":"Hematology\/oncology and stem cell therapy."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"issue":"10","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty M","year":"2018","unstructured":"Mohty M, Terpos E, Mateos M-V, Cavo M, Lejniece S, Beksac M, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clinical Lymphoma Myeloma and Leukemia. 2018;18(10):e401\u2013e19.","journal-title":"Clinical Lymphoma Myeloma and Leukemia."},{"issue":"5","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.12685","article-title":"Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population","volume":"164","author":"Liwing J","year":"2014","unstructured":"Liwing J, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, et al. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. British journal of haematology. 2014;164(5):684\u201393.","journal-title":"British journal of haematology."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"issue":"1","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2020.8267","article-title":"Comparison of bortezomibcyclophosphamide-dexamethasone versus bortezomibdexamethasone based regimens in newly diagnosed multiple myeloma patients","volume":"12","author":"Ciftciler R","year":"2020","unstructured":"Ciftciler R, Goker H, Buyukasik Y, Say\u0131nalp N, Haznedaroglu IC, Aksu S, et al. Comparison of bortezomibcyclophosphamide-dexamethasone versus bortezomibdexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematology reports. 2020;12(1).","journal-title":"Hematology reports."},{"issue":"2","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3747\/co.27.5385","article-title":"Cyclophosphamide\u2013bortezomib\u2013dexamethasone compared with bortezomib\u2013dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma","volume":"27","author":"Figueiredo A","year":"2020","unstructured":"Figueiredo A, Atkins H, Mallick R, Kekre N, Kew A, McCurdy A. Cyclophosphamide\u2013bortezomib\u2013dexamethasone compared with bortezomib\u2013dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma. Current Oncology. 2020;27(2):81\u20135.","journal-title":"Current Oncology."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.288"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"issue":"3","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma","volume":"156","author":"Khan ML","year":"2012","unstructured":"Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, et al. A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma. British journal of haematology. 2012;156(3):326\u201333.","journal-title":"British journal of haematology."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"issue":"3","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41409-020-01086-9","article-title":"Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres","volume":"56","author":"McCaughan GJ","year":"2021","unstructured":"McCaughan GJ, Verma A, Ling S, Lavee O, Moore JJ, Bryant A. Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres. Bone Marrow Transplantation. 2021;56(3):738\u201340.","journal-title":"Bone Marrow Transplantation."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271676"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70081-x"},{"key":"e_1_3_2_21_2","volume-title":"Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)","author":"Kumar SK","year":"2013","unstructured":"Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, et al. Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM). American Society of Hematology Washington, DC; 2013."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.214"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267"},{"issue":"12","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/sj.bmt.1704286","article-title":"A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents","volume":"32","author":"Lerro K","year":"2003","unstructured":"Lerro K, Medoff E, Wu Y, Seropian S, Snyder E, Krause D, et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone marrow transplantation. 2003;32(12):1113\u20137.","journal-title":"Bone marrow transplantation."},{"issue":"5","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","article-title":"Lowdose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma","volume":"31","author":"Jantunen E","year":"2003","unstructured":"Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T, Mahlam\u00e4ki E, Remes K. Lowdose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone marrow transplantation. 2003;31(5):347\u201351.","journal-title":"Bone marrow transplantation."},{"issue":"9","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie BG","year":"2006","unstructured":"Durie BG, Harousseau J, Miguel J, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.225"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14920"},{"issue":"3","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/bmt.2014.288","article-title":"CyBorD induction therapy in clinical practice","volume":"50","author":"Areethamsirikul N","year":"2015","unstructured":"Areethamsirikul N, Masih-Khan E, Chu C, Jimenez-Zepeda V, Reece D, Trudel S, et al. CyBorD induction therapy in clinical practice. Bone marrow transplantation. 2015;50(3):375\u20139.","journal-title":"Bone marrow transplantation."},{"issue":"9758","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo M","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet. 2010;376(9758):2075\u201385.","journal-title":"The Lancet."},{"issue":"8","key":"e_1_3_2_32_2","first-page":"1589","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol L","year":"2012","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, Hern\u00e1ndez D, L\u00f3pez-Jim\u00e9nez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood, The Journal of the American Society of Hematology. 2012;120(8):1589\u201396.","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"10","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.clml.2019.09.597","article-title":"VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III, randomized study","volume":"19","author":"Kumar L","year":"2019","unstructured":"Kumar L, kumar Chellapuram S, Sahoo R, Gupta R. VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III, randomized study. Clinical Lymphoma, Myeloma and Leukemia. 2019;19(10):e361.","journal-title":"Clinical Lymphoma, Myeloma and Leukemia."},{"issue":"36","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor P","year":"2013","unstructured":"Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. Journal of Clinical Oncology. 2013;31(36):4529.","journal-title":"Journal of Clinical Oncology."},{"issue":"3","key":"e_1_3_2_35_2","first-page":"363","article-title":"Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country","volume":"38","author":"Sch\u00fctz NP","year":"2020","unstructured":"Sch\u00fctz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, et al. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma M\u00faltiple. Hematological oncology. 2020;38(3):363\u201371.","journal-title":"A Retrospective Cohort Study from Grupo Argentino de Mieloma M\u00faltiple. Hematological oncology."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.6679"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T12:54:36Z","timestamp":1713272076000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2024.93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.5144\/0256-4947.2024.93"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2024.93","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}